Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSXV:HMR
TSXV:HMRMetals and Mining

TSX Penny Stock Gems: Homerun Resources Among 3 Compelling Picks

As 2025 draws to a close, Canadian markets have experienced robust growth, with the TSX delivering impressive double-digit gains. In such a thriving market landscape, investors often look beyond established giants to uncover hidden opportunities in lesser-known areas. Penny stocks, though an outdated term, still represent intriguing prospects for those seeking growth potential at lower price points. In this article, we explore three compelling penny stocks that stand out for their strong...
NYSE:LXFR
NYSE:LXFRMachinery

Discovering US Undiscovered Gems December 2025

As the Federal Reserve's anticipated rate cut looms, the U.S. stock market presents a mixed picture with major indices showing varied performances. Amidst this backdrop, small-cap stocks have gained attention for their potential to outperform in a declining interest-rate environment, offering investors opportunities to uncover lesser-known companies poised for growth. In such conditions, identifying stocks with strong fundamentals and resilience becomes crucial for those seeking undiscovered...
NYSE:RYN
NYSE:RYNSpecialized REITs

Three Dividend Stocks To Enhance Your Portfolio

As the U.S. market navigates mixed signals ahead of a crucial Federal Reserve decision on interest rates, investors are keenly observing how these changes might impact their portfolios. In such an environment, dividend stocks can offer a stable income stream and potential for growth, making them a valuable consideration for those looking to enhance their investment strategy amidst fluctuating economic conditions.
SEHK:3360
SEHK:3360Diversified Financial

Will Far East Horizon’s New Board Structure (SEHK:3360) Deepen Governance Strength Or Add Complexity?

Far East Horizon recently reshaped its board structure, detailing the roles of directors and establishing four committees covering audit and risk management, remuneration and nomination, strategy and investment, and environmental, social and governance oversight. The appointment of Mr. Liu Jialin as lead independent director marks a governance shift designed to strengthen board effectiveness and shareholder engagement under updated listing and corporate governance rules. We'll now examine...
SEHK:3393
SEHK:3393Electronic

Wasion Holdings (SEHK:3393) Is Up 5.2% After Hitting Record Highs on Energy-Efficiency Push

In recent days, Wasion Holdings reported achieving record high stock prices, reflecting strong investor interest in its energy metering and management solutions across multiple regions. This momentum highlights how Wasion’s expansion into energy-efficient technologies and broader international markets is reshaping its role within Hong Kong’s energy management sector. We’ll now examine how this renewed confidence in Wasion’s energy-efficiency expansion informs the company’s investment...
TSXV:SNM
TSXV:SNMOil and Gas

TSX Value Picks Estimated To Be Trading Up To 49% Below Intrinsic Value

As we approach the end of 2025, Canadian markets have shown impressive resilience with the TSX posting a robust 27% gain year-to-date, while investors keenly observe potential catalysts such as central bank meetings and labor market reports. In this environment of cautious optimism, identifying undervalued stocks becomes crucial for investors seeking to capitalize on opportunities that may be trading below their intrinsic value.
ASX:IMM
ASX:IMMBiotechs

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...